UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:ANKRD24_DAPK3 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: ANKRD24_DAPK3 | KinaseFusionDB ID: KFG360 | FusionGDB2.0 ID: KFG360 | Hgene | Tgene | Gene symbol | ANKRD24 | DAPK3 | Gene ID | 170961 | 1613 | |
Gene name | ankyrin repeat domain 24 | death associated protein kinase 3 | ||||||||||
Synonyms | - | DLK|ZIP|ZIPK | ||||||||||
Cytomap | 19p13.3 | 19p13.3 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | ankyrin repeat domain-containing protein 24 | death-associated protein kinase 3DAP kinase 3DAP-like kinaseMYPT1 kinaseZIP-kinasezipper-interacting protein kinase | ||||||||||
Modification date | 20240305 | 20240305 | ||||||||||
UniProtAcc | Q8TF21 | O43293 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000595096, ENST00000262970, ENST00000318934, ENST00000600132, | ENST00000301264, ENST00000545797, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: ANKRD24 [Title/Abstract] AND DAPK3 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ANKRD24(4210369)-DAPK3(3964989), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | DAPK3 | GO:0006468 | protein phosphorylation | 10356987 |
Tgene | DAPK3 | GO:0006915 | apoptotic process | 10580117 |
Tgene | DAPK3 | GO:0017148 | negative regulation of translation | 18995835 |
Tgene | DAPK3 | GO:0032956 | regulation of actin cytoskeleton organization | 23454120 |
Tgene | DAPK3 | GO:0035556 | intracellular signal transduction | 10356987 |
Tgene | DAPK3 | GO:0043065 | positive regulation of apoptotic process | 21487036 |
Tgene | DAPK3 | GO:0046777 | protein autophosphorylation | 18239682 |
Tgene | DAPK3 | GO:0051893 | regulation of focal adhesion assembly | 23454120 |
Tgene | DAPK3 | GO:0071346 | cellular response to type II interferon | 18995835 |
Kinase Fusion gene breakpoints across ANKRD24 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across DAPK3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChimerDB4 | SPNT_312 | ANKRD24 | chr19 | 4210369 | DAPK3 | chr19 | 3964989 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:4210369/:3964989) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ANKRD24 | DAPK3 |
FUNCTION: Componement of the stereocilia rootlet in hair cells of inner ear. Bridges the apical plasma membrane with the lower rootlet and maintains normal distribution of TRIOBP, thereby reinforcing stereocilia insertion points and organizing rootlets for hearing with long-term resilience. {ECO:0000250|UniProtKB:Q80VM7}. | FUNCTION: Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization. Involved in the regulation of smooth muscle contraction. Regulates both type I (caspase-dependent) apoptotic and type II (caspase-independent) autophagic cell deaths signal, depending on the cellular setting. Involved in regulation of starvation-induced autophagy. Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. In smooth muscle, regulates myosin either directly by phosphorylating MYL12B and MYL9 or through inhibition of smooth muscle myosin phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to enhance muscle responsiveness to Ca(2+) and promote a contractile state. Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of actin stress fibers into thick bundles. Involved in actin filament focal adhesion dynamics. The function in both reorganization of actin cytoskeleton and focal adhesion dissolution is modulated by RhoD. Positively regulates canonical Wnt/beta-catenin signaling through interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon interferon-gamma activation which is causing RPL13A release from the ribosome, RPL13A association with the GAIT complex and its subsequent involvement in transcript-selective translation inhibition. Enhances transcription from AR-responsive promoters in a hormone- and kinase-dependent manner. Involved in regulation of cell cycle progression and cell proliferation. May be a tumor suppressor. {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323, ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990, ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of ANKRD24_DAPK3 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
DAPK3 | O43293 | human | PPP1R14A | Q96A00 | S12 | rLGKRVLsKLQsPSr | PP1_inhibitor |
DAPK3 | O43293 | human | DAPK3 | O43293 | T306 | tTRLkEytIksHssL | |
DAPK3 | O43293 | human | DAPK3 | O43293 | S311 | EytIksHssLPPNNS | |
DAPK3 | O43293 | human | LMO7 | Q8WWI1-3 | S863 | LKNLKRRsQFFEQGS | |
DAPK3 | O43293 | human | MYL9 | P24844 | T19 | KKRPQRAtsNVFAMF | |
DAPK3 | O43293 | human | PPP1R14A | Q96A00 | T38 | QkRHARVtVkYDRRE | PP1_inhibitor |
DAPK3 | O43293 | human | MDM2 | Q00987 | S186 | RQRkRHksDsIsLsF | |
DAPK3 | O43293 | human | CDKN1A | P38936 | T145 | QGRkRRQtsMTDFyH | |
DAPK3 | O43293 | human | BECN1 | Q14457 | S90 | IPPARMMstEsANsF | |
DAPK3 | O43293 | human | TRIP12 | Q14669 | S312 | STKkRsEsPPAELPs | |
DAPK3 | O43293 | human | MDM2 | Q00987 | S166 | SsRRRAIsEtEENsD | |
DAPK3 | O43293 | human | RPL13A | P40429 | S77 | PYHFrAPsRIFWRTV | Ribosomal_L13 |
DAPK3 | O43293 | human | MYL12B | O14950 | S20 | KRPQRAtsNVFAMFD | |
DAPK3 | O43293 | human | TP53 | P04637 | S20 | PLsQEtFsDLWkLLP | P53_TAD |
DAPK3 | O43293 | human | DAPK3 | O43293 | T180 | EFKNIFGtPEFVAPE | Pkinase |
DAPK3 | O43293 | human | MYL9 | P24844 | S20 | KRPQRAtsNVFAMFD | |
DAPK3 | O43293 | human | DAPK3 | O43293 | T225 | LGETKQEtLTNISAV | Pkinase |
DAPK3 | O43293 | human | DAPK3 | O43293 | T265 | KDPKRRMtIAQSLEH | Pkinase |
DAPK3 | O43293 | human | MYL12B | O14950 | T19 | KKRPQRAtsNVFAMF | |
DAPK3 | O43293 | human | CDC14A | Q9UNH5 | S484 | INSRLASsLGNLNAA | |
DAPK3 | O43293 | human | DAPK3 | O43293 | T299 | PERRRLKtTRLkEyt |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
DAPK3 | ID | Description | 0.00e+00 |
DAPK3 | GO:0006977 | DNA damage respons | 1.59e-07 |
DAPK3 | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 1.33e-04 |
DAPK3 | GO:0044819 | mitotic G1/S transition checkpoint signaling | 1.33e-04 |
DAPK3 | GO:0010332 | response to gamma radiation | 6.00e-04 |
DAPK3 | GO:0071479 | cellular response to ionizing radiation | 1.19e-03 |
DAPK3 | GO:0030330 | DNA damage respons | 1.19e-05 |
DAPK3 | GO:0044773 | mitotic DNA damage checkpoint signaling | 1.19e-03 |
DAPK3 | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 1.19e-03 |
DAPK3 | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 1.19e-03 |
DAPK3 | GO:0044774 | mitotic DNA integrity checkpoint signaling | 1.19e-03 |
DAPK3 | GO:0031668 | cellular response to extracellular stimulus | 1.19e-03 |
DAPK3 | GO:0034644 | cellular response to UV | 1.19e-03 |
DAPK3 | GO:0071236 | cellular response to antibiotic | 1.21e-03 |
DAPK3 | GO:1902807 | negative regulation of cell cycle G1/S phase transition | 1.23e-03 |
DAPK3 | GO:0010225 | response to UV-C | 1.47e-03 |
DAPK3 | GO:0097193 | intrinsic apoptotic signaling pathway | 1.48e-03 |
DAPK3 | GO:0070482 | response to oxygen levels | 1.70e-03 |
DAPK3 | GO:0071496 | cellular response to external stimulus | 1.70e-03 |
DAPK3 | GO:0090399 | replicative senescence | 1.70e-03 |
DAPK3 | GO:0071346 | cellular response to type II interferon | 1.70e-03 |
DAPK3 | GO:1901990 | regulation of mitotic cell cycle phase transition | 1.70e-03 |
DAPK3 | GO:0006978 | DNA damage respons | 5.64e-05 |
DAPK3 | GO:0000077 | DNA damage checkpoint signaling | 1.74e-03 |
DAPK3 | GO:0042772 | DNA damage respons | 6.30e-05 |
DAPK3 | GO:0010212 | response to ionizing radiation | 2.06e-03 |
DAPK3 | GO:0007093 | mitotic cell cycle checkpoint signaling | 2.15e-03 |
DAPK3 | GO:0034341 | response to type II interferon | 2.15e-03 |
DAPK3 | GO:2000377 | regulation of reactive oxygen species metabolic process | 2.26e-03 |
DAPK3 | GO:0009411 | response to UV | 2.42e-03 |
DAPK3 | GO:0009410 | response to xenobiotic stimulus | 2.59e-03 |
DAPK3 | GO:1901987 | regulation of cell cycle phase transition | 3.04e-03 |
DAPK3 | GO:0010165 | response to X-ray | 3.09e-03 |
DAPK3 | GO:0010039 | response to iron ion | 3.10e-03 |
DAPK3 | GO:0044772 | mitotic cell cycle phase transition | 3.10e-03 |
DAPK3 | GO:0072331 | signal transduction by p53 class mediator | 3.10e-03 |
DAPK3 | GO:0009267 | cellular response to starvation | 3.21e-03 |
DAPK3 | GO:0071478 | cellular response to radiation | 3.21e-03 |
DAPK3 | GO:0016242 | negative regulation of macroautophagy | 3.21e-03 |
DAPK3 | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 3.21e-03 |
DAPK3 | GO:0031667 | response to nutrient levels | 3.32e-03 |
DAPK3 | GO:0042770 | signal transduction in response to DNA damage | 3.35e-03 |
DAPK3 | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 3.35e-03 |
DAPK3 | GO:0000075 | cell cycle checkpoint signaling | 3.38e-03 |
DAPK3 | GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 3.39e-03 |
DAPK3 | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 3.45e-03 |
DAPK3 | GO:0046677 | response to antibiotic | 3.57e-03 |
DAPK3 | GO:2000279 | negative regulation of DNA biosynthetic process | 3.57e-03 |
DAPK3 | GO:0043516 | regulation of DNA damage respons | 2.57e-04 |
DAPK3 | GO:1902806 | regulation of cell cycle G1/S phase transition | 3.78e-03 |
Top |
Related Drugs to ANKRD24_DAPK3 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning ANKRD24-DAPK3 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to ANKRD24_DAPK3 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |